KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.

Kubota Pharmaceutical Holdings Co., Ltd.

4596

JP3266500002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:00:00 17/05/2024 BST			5-day change	1st Jan Change
69 ^JPY	+1.47%		-1.43%	-13.75%

03-22	Kubota Pharmaceutical Adjusts 2023 Financial Results Following Reevaluation	MT
03-21	Kubota Pharmaceutical Holdings Co., Ltd. Restates Consolidated and Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2023	CI

Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021

February 12, 2021 at 08:30 am

Kubota Pharmaceutical Holdings Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2021. For the period, the company expected revenue of JPY 10 million, operating loss of JPY 2,900 million, net loss of JPY 2,800 million and basic loss per share of JPY 62.84.

Latest news about Kubota Pharmaceutical Holdings Co., Ltd.

Kubota Pharmaceutical Adjusts 2023 Financial Results Following Reevaluation	03-22	MT
Kubota Pharmaceutical Holdings Co., Ltd. Restates Consolidated and Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2023	03-21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-14	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	10/08/23	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/02/23	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	11/11/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	11/11/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. announced that it expects to receive ¥3.1 million in funding from Barclays Bank PLC, Investment Arm	14/08/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	12/08/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	12/08/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Announces Database Lock for Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease and Expected Release of Top-Line Results in August 2022	27/07/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	13/05/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022	14/02/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2021	12/11/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Consolidated Financial Results for the Six Months Ended June 30, 2021	12/08/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending Dec. 31, 2021	12/08/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2021	13/05/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Earnings Guidance for the Full Year Ending December 31, 2021	13/05/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020	12/02/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	12/02/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. announced that it has received ¥4.59 million in funding from Barclays Bank PLC, Investment Arm	12/07/20	CI
Kubota Pharmaceutical Holdings Co., Ltd. announced that it expects to receive ¥4.59 million in funding from Barclays Bank PLC, Investment Arm	25/06/20	CI

Chart Kubota Pharmaceutical Holdings Co., Ltd.

Duration

Period

Chart Kubota Pharmaceutical Holdings Co., Ltd.

More charts

Company Profile

Kubota Pharmaceutical Holdings Co., Ltd. is a Japan-based company mainly engaged in the operation and management of subsidiaries. Its subsidiaries are mainly engaged in discovering and developing drug candidates to treat and slow the progression of sight-threatening ophthalmic diseases. The Company operates pharmaceutical development segment. It focuses on the development of oral formulation for age-related macular degeneration (AMD), glaucoma and dry eye syndrome.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.	-13.75%	24.66M
ELI LILLY AND COMPANY	+32.36%	694B
NOVO NORDISK A/S	+30.00%	593B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+14.47%	239B
NOVARTIS AG	+10.32%	209B
ROCHE HOLDING AG	-3.15%	209B
AMGEN INC.	+9.27%	169B

Other Pharmaceuticals